| Literature DB >> 34522637 |
Reem Ashraf Elnahas1, Bassma Hassan Elwakil2, Salma Sameh Elshewemi3, Zakia Ahmed Olama1.
Abstract
BACKGROUND AND AIM: In vitro activity evaluation of Egyptian Olea europaea leaves extracts, and in vivo healing activity assessment of the newly prepared ointment of Olea europaea leaves extracts mingled with Shea butter. EXPERIMENTAL PROCEDURE: Different extraction methods and solvents were used to extract Egyptian Olea europaea bioactive agent(s). Antibacterial, scavenging activity and in-vivo evaluation of wound repair potentiality of Olea europaea extract were examined in normal and diabetic experimental rat models with induced circular excisions. RESULTS ANDEntities:
Keywords: Antimicrobial activity; MRSA; Olea europaea; Oleuropein; Wound healing
Year: 2021 PMID: 34522637 PMCID: PMC8427474 DOI: 10.1016/j.jtcme.2021.02.008
Source DB: PubMed Journal: J Tradit Complement Med ISSN: 2225-4110
Minimum inhibitory concentrations of all tested Olea europaea leaf samplesa against MDR bacteria.
| Microorganisms | MIC values (μg/mL) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tanta LEM | Alexandria LEM | Marsa Matrouh LEM | Siwa Oasis LEM | |||||||||
| MIC | MBC | MIC Index | MIC | MBC | MIC Index | MIC | MBC | MIC Index | MIC | MBC | MIC Index | |
| 125 | 375 | 3 | 125 | 500 | 4 | 62.5 | 250 | 4 | 125 | 375 | 3 | |
| MRSA 1 | 15.6 | 31.2 | 2 | 125 | 375 | 3 | 250 | 1000 | 4 | 15.6 | 31.2 | 2 |
| 15.6 | 62.4 | 4 | 250 | 750 | 3 | 125 | 500 | 4 | 125 | 250 | 2 | |
| 62.5 | 250 | 4 | 125 | 625 | 5 | 250 | 1000 | 4 | 15.6 | 31.2 | 2 | |
| 62.5 | 250 | 4 | 15.6 | 62.4 | 4 | 125 | 1000 | 8 | 250 | 750 | 3 | |
| 15.6 | 31.2 | 2 | 125 | 625 | 5 | 250 | 750 | 3 | 62.5 | 125 | 2 | |
| 125 | 375 | 3 | 250 | 750 | 3 | 125 | 375 | 3 | 62.5 | 125 | 2 | |
| MRSA 2 | 15.6 | 31.2 | 2 | 52.5 | 210 | 4 | 62.5 | 375 | 6 | 15.6 | 62.4 | 4 |
| MRSA 3 | 15.6 | 31.2 | 2 | 125 | 750 | 6 | 125 | 250 | 2 | 62.5 | 125 | 2 |
| 15.6 | 62.4 | 4 | 250 | 750 | 3 | 125 | 500 | 4 | 125 | 500 | 4 | |
Ethanol extraction using maceration technique.
The code used 1, 2, and 3 was applied to enumerate different clinical isolates however the full data was demonstrated in supplementary file.
Fig. 1TEM for MRSA cells; untreated (a) and treated (b) with Tanta LEM extract.
Fig. 2GC-MS chromatogram of the crude Tanta LEM extract.
Retention time (RT) and probable compounds according to MS library.
| Group | R.T. (min) | Suggested compound | M.W. | M.F. | Content % |
|---|---|---|---|---|---|
| Ester | 11.78 | Benzoic acid, 4-formyl-, methyl ester | 164 | C9H8O3 | 6.30 |
| 18.18 | Dasycarpidan-1-methanol, acetate (ester) | 540 | C25H32O13 | 19.10 | |
| 19.13 | 3-(2,6,6-Trimethyl-cyclohex-1-enyl)-propionic acid, methyl ester | 210 | C13H22O2 | 4.60 | |
| 19.45 | Benzenepropanoic acid, 3,4-dihydroxy-, methyl ester | 196 | C10H12O4 | 5.80 | |
| 22.24 | Hexadecanoic acid, ethyl ester | 284 | C18H36O2 | 5.50 | |
| 25.23 | Linoleic acid ethyl ester | 308 | C20H36O2 | 11.30 | |
| 25.53 | Ethyl Oleate | 310 | C20H38O2 | 8.10 | |
| 27.28 | Tributyl acetylcitrate | 402 | C20H34O8 | 4.30 | |
| 31.87 | Phenyl 2,3,4,6-tetra-O-acetyl-β-d-glucopyranoside | 424 | C20H24O10 | 6.50 | |
| 35.36 | Cellobioseoctaacetate | 678 | C28H38O19 | 4.00 | |
| 49.24 | Ergosta-5,22-dien-3-ol, acetate, (3β,22E) | 440 | C30H48O2 | 2.50 | |
| Aldehyde | 15.94 | 9,10-Secochola-5,7,10(19)-trien-24-al, 3-hydroxy-, (3β,5Z,7E) | 356 | C24H36O2 | 10.20 |
| Alcohol | 41.49 | dl-α-Tocopherol | 430 | C29H50O2 | 3.60 |
| 10.79 | 2-Methoxy-4-vinylphenol | 150 | C9H10O2 | 4.80 | |
| Aromatic | 49.78 | 1-Monolinoleoylglycerol trimethylsilyl ether | 498 | C27H54O4Si2 | 3.40 |
M.W.: Molecular Weight, M.F.: Molecular Formula.
Synergy test of Tanta LEM crude extract in combination with commonly known antibiotics.
| Antibacterial agent | Single drug | Combined drug | FIC | FICI | Interpretation | ||
|---|---|---|---|---|---|---|---|
| MIC (μg/ml) | IZ (mm) | MIC (μg/ml) | IZ (mm) | ||||
| Tanta LEM crude extract | 15.60 | 15.00 | 3.90 | 0.25 | |||
| Vancomycin | 125.00 | 12.00 | 143.75 | 12.00 | 1.15 | 1.40 | Indifferent |
| Ciprofloxacin | 250.00 | 20.00 | 37.50 | 37.00 | 0.15 | 0.40 | Synergy |
| Amikacin | 250.00 | 10.00 | 200.00 | 10.00 | 0.80 | 1.05 | Indifferent |
| Imipenem | 62.00 | 16.00 | 108.50 | 16.00 | 1.75 | 2.00 | Indifferent |
Fig. 3Morphological appearance of wound healing during time intervals in diabetic and non-diabetic rats∗. ∗ Group 8 (treated with 1:3 shea butter: Tanta LEM/CIP (w/v)).
Bacterial cell load in non-diabetic and diabetic animal tissues after treatment at time intervals.
| Group | MRSA viable log10 CFU/g tissue | |||
|---|---|---|---|---|
| Non-diabetic rat group | Day 3 | Day 6 | Day 9 | Day 13 |
| 1: Negative control | 9.1 | 8.3 | 7.2 | 3.5 |
| 2: Positive control | 9.9 | 9.5 | 9.1 | 8.4 |
| 3: Treated with shea butter | 9.2 | 7.1 | 6.2 | 5.0 |
| 4: Treated with Ciprofloxacin | 8.5 | 6.1 | 5.5 | 1.8 |
| 5: Treated with Tanta LEM | 8.5 | 5.7 | 4.3 | 1.5 |
| 6: Treated with ointment 1 | 7.3 | 5.5 | 3.1 | 0.9 |
| 7: Treated with ointment 2 | 6.8 | 3.9 | 1.9 | 0.5 |
| 8: Treated with ointment 3 | 5.9 | 2.9 | 0.1 | 0.0 |
| Diabetic rat group | ||||
| 1: Negative control | 9.7 | 9.1 | 8.5 | 8.1 |
| 2: Positive control | 9.8 | 9.8 | 9.7 | 9.5 |
| 3: Treated with shea butter | 9.2 | 8.5 | 7.9 | 7.5 |
| 4: Treated with Ciprofloxacin | 9.1 | 7.8 | 6.8 | 6.1 |
| 5: Treated with Tanta LEM | 8.9 | 8.1 | 7.6 | 7.2 |
| 6: Treated with ointment 1 | 7.9 | 6.3 | 5.4 | 4.8 |
| 7: Treated with ointment 2 | 7.8 | 5.2 | 3.2 | 2.3 |
| 8: Treated with ointment 3 | 6.1 | 3.4 | 1.4 | 0.3 |
(1:1 w/v shea butter: Tanta LEM/Ciprofloxacin).
(1:2 w/v shea butter: Tanta LEM/Ciprofloxacin).
(1:3 w/v shea butter: Tanta LEM/Ciprofloxacin).
Fig. 4Light micrograph (X 100) of V.S. in wounded skin of a) Non-diabetic wounded rat skin of group 1 (negative control), showing dermis (D) with irregular distributed collagen fibers, hair follicle (arrowheads) and sebaceous gland (arrows). b) Diabetic wounded rat skin of group 1 (negative control), showing thinning of epidermis (E), dermis (D) with irregular distributed collagen fibers, hair follicle (arrowheads) and sebaceous gland (arrows). c) Non-diabetic wounded rat skin of group 2 (positive control), showing new blood vessel formation within the wound area indicating angiogenesis. (D). d) Diabetic wounded rat skin of group 2 (positive control), showing dermis (D) with irregular distributed collagen fibers. Double arrows demonstrate the epithelial migration of keratinocytes beneath the scab (S), inflammatory cells (I) in newly formed dermis. Note: intense number of new blood vessel observed (∗). e) Non-diabetic rats after treatment with ointment 3, showing, epithelial migration of keratinocytes (double arrows) beneath the scab (S), microvessel (∗), intense number of new blood vessel observed (arrows) and dermis (D). f) diabetic rats after treatment with ointment 3, showing, epidermal moving (double arrows), moderate inflammatory cells in newly formed dermis (D) and high density of microvessel (∗), epidermal moving (double arrows), moderate inflammatory cells in newly formed dermis (D) and high density of microvessel (∗).